Vasopressin and related peptides: animal and human studies.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  Progress in Neuro-psychopharmacology and Biological Psychiatry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/0278-5846(85)90016-8PMID 3911283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of vasopressin treatment on learning in Down's syndrome

  2005cited by this paper
• A critique of the vasopressin-memory hypothesis

  2004cited by this paper
• Neuropeptides and cognitive disorders.

  1986cited by this paper
• Immunocytochemical localization of vasopressin in the human brain; its possible consequences for therapeutic strategies in aging and dementia.

  1986cited by this paper
• Disrupting circadian rhythms in rats induces retrograde amnesia.

  1985cited by this paper
• The effect of vasopressin on memory in the healthy elderly.

  1984cited by this paper
• Central target for the behavioural effects of vasopressin neuropeptides

  1984cited by this paper
• Vasopressin in Neuropsychiatric Disorders

  1984cited by this paper
• Does vasopressin really facilitate memory processes

  1984cited by this paper
• Morphology of vasopressin and oxytocin neurones and their central and vascular projections.

  1983cited by this paper
• DESGLYCINAMIDE9-ARGININE8-VASOPRESSIN AND AMBULANT METHADONE-DETOXIFICATION OF HEROIN ADDICTS

  1983cited by this paper
• Effect of vasopressin on memory following electroconvulsive therapy.

  1983cited by this paper
• Vasopressin-like peptides and the treatment of memory disorders in man.

  1983cited by this paper
• A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide.

  1983cited by this paper
• Effects of desglycinamide-arginine-vasopressin (DG-AVP) on memory processes in diabetes insipidus patients and non-diabetic subjects.

  1983cited by this paper
• Neurophysines, vasopressine et fonctions cognitives au cours du vieillissement

  1983cited by this paper
• Vasopressin and memory.

  1983cited by this paper
• Vasopressin and oxytocin: distribution and putative functions in the brain.

  1983cited by this paper
• Neurohypophyseal hormones and brain neurochemistry.

  1982cited by this paper
• A placebo‐controlled trial shows no effect of vasopressin on recovery from closed head injury

  1982cited by this paper
• Neurohypophysial hormones and addiction

  1980cited by this paper
• Vasopressin therapy in Parkinson's disease

  1980cited by this paper
• The development of food search behavior by rats: the effects of hippocampal damage and haloperidol.

  1978cited by this paper
• Neurohypophyseal principles and memory processes.

  1978cited by this paper
• Effects of vasopressin on active and passive avoidance behavior.

  1972cited by this paper
• The influence of the posterior and inter-mediate lobe of the pituitary and pituitary peptides on the maintenance of a conditioned avoidance response in rats

  1965cited by this paper
• THE INFLUENCE OF THE POSTERIOR AND INTERMEDIATE LOBE OF THE PITUITARY AND PITUITARY PEPTIDES ON THE MAINTENANCE OF A CONDITIONED AVOIDANCE RESPONSE IN RATS.

  1965cited by this paper

• Astrocytic glycogenolysis: mechanisms and functions

  2014cites this paper
• The effects of vasopressin and oxytocin on methamphetamine–induced place preference behaviour in rats

  2012cites this paper
• Emotion and episodic memory in neuropsychiatric disorders.

  2010cites this paper
• 82 – Neuroregulatory Peptides of Central Nervous System Origin: From Laboratory to Clinic

  2009cites this paper
• Functional activity of vasopressin analog desglycinamide-arginine-vasopressin

  2006cites this paper
• Sleep associated endocrine and immune changes in the elderly

  2005cites this paper
• Neuropeptides: Animal behaviour and human psychopathology

  2004cites this paper
• Glucocorticoid Withdrawal Syndrome

  2004cites this paper
• Does DGAVP influence memory, attention and mood in young healthy men?

  2004cites this paper
• Endocrine withdrawal syndromes.

  2003cites this paper
• Neuroregulatory Peptides of Central Nervous System Origin: From Bench to Bedside

  2002cites this paper
• ADH and oxytocin in age-related minor cognitive impairment

  1997cites this paper
• Safety and Clinical Efficacy of S12024 in Patients with Mild to Moderate Alzheimer’s Disease

  1997cites this paper
• Exercise dependence and associated disorders: A review

  1996cites this paper
• Sleep and signs of attention during 3 months of intranasal vasopressin: a pilot study in two elderly subjects.

  1996cites this paper
• Effect of acute and chronic treatment with desglycinamide-[Arg8]vasopressin in young male and female volunteers.

  1995cites this paper
• Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects.

  1994cites this paper
• Neuropeptides and psychopathology

  1994cites this paper
• Desglycinamide‐(Arg8)‐vasopressin in five trials with memory‐disturbed patients

  1992cites this paper
• Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder.

  1992cites this paper
• Effect of a single dose of des-glycinamide-[Arg8]vasopressin or oxytocin on cognitive processes in young healthy subjects.

  1992cites this paper
• Neuropeptides as psychotropic drugs

  1992cites this paper
• Modulation of memory retrieval by pre-testing vasopressin: involvement of a central cholinergic nicotinic mechanism.

  1992cites this paper
• Neuropeptides related to [Arg8]vasopressin facilitates social recognition in rats.

  1991cites this paper
• Behavioral effects of neurohypophyseal peptides in healthy volunteers: 10 years of research.

  1991cites this paper
• Opposite action of oxytocin and its peptide antagonists on social memory in rats.

  1991cites this paper
• Vasopressin(1-8) (des-glycinamide9-[Arg8]vasopressin) is an endogenous peptide present in rat plasma.

  1991cites this paper
• RECOGNITION CUE IN THE RAT'S SOCIAL MEMORY PARADIGM

  1991cites this paper
• β Down-regulation induced by repeated vasopressin treatment

  1990cites this paper
• Beta down-regulation induced by repeated vasopressin treatment.

  1990cites this paper
• DGAVP (Org 5667) in early Alzheimer's disease patients

  1990cites this paper
• Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects.

  1990cites this paper
• Behavioral effects of vasopressin

  1990cites this paper
• Clinical efficacy of 1‐desamino‐8‐d‐arginine‐vasopressin (DDAVP) in short‐term recovery from minor head injury

  1989cites this paper
• Human memory: psychology, pathology and pharmacology

  1989cites this paper
• Facilitation of inhibitory avoidance by hypertonic saline is reversed by a vasopressin and a nicotinic antagonist.

  1989cites this paper
• Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications.

  1989cites this paper
• Transdermal permeation of vasopressin. I. Influence of pH, concentration, shaving and surfactant on in vitro permeation

  1989cites this paper
• Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory.

  1989cites this paper
• Hormonal Regulation of Learning Performance

  1989cites this paper
• Vasopressin modulates the activity of nicotinic cholinergic mechanisms during memory retrieval in mice.

  1988cites this paper
• Vasopressin and vasopressin analogues for treatment of memory disorders in clinical practice.

  1988cites this paper
• Differential effect of desglycinamide9-(Arg8)-vasopressin on cognitive functions of diabetes insipidus and alcoholic patients.

  1987cites this paper
• The neuropeptide concept.

  1987cites this paper
• Chapter 9 The neuropeptide concept

  1987cites this paper
• Enhanced monoaminergic neurotransmission by desglycinamide-arginine-vasopressin in human subjects.

  1987cites this paper
• Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects.

  1987cites this paper
• Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats.

  1986cites this paper